Open label, non-randomised study of efficacy and safety of intravitreal bevacizumab biosimilar in retinal diseases (BIRD) - BIRD

V Prasad Eye Institute0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Center-involved macular edema or sub-retinal fluid or any subretinal hemorrhage secondary to diabetic macular edema, proliferative diabetic retinopathy, age related macular degeneration and retinal vein occlusion
•2 .Adults more than/ equal to 18 years of age
•3. ETDRS BCVA of 20/30 to 20/800 in the study eye
•4. Men and women of childbearing potential must be willing to utilize adequate
•contraception and not become pregnant (or have their partner[s] become
•pregnant during the full course of the study
•5. Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures
•6. Willingness to provide written informed consent

•1. History of vitreoretinal surgery in the study eye or anticipated within the next 12 months following Day 1
•2. Previous treatment with anti-angiogenic drugs in the study eye or fellow eye in the past 3 months
•3.Ocular inflammation (including trace or above) or external ocular inflammation in the study eye
•4. History of idiopathic or autoimmune uveitis in either eye
•5. Uncontrolled glaucoma, defined as IOP >= 25mmHg on optimal medical regimen, in either the study eye or fellow eye or previous filtration surgery in either the study eye or fellow eye

发起方

V Prasad Eye Institute